Nationwide neonatal screening for congenital adrenal hyperplasia in sweden: a 26-year longitudinal prospective population-based study.

IMPORTANCE Recent reports have questioned the rationale for neonatal screening for congenital adrenal hyperplasia (CAH) owing to low sensitivity in salt-wasting forms and a high rate of recall (ie, a positive finding resulting in a visit to a pediatrician and a second test) in preterm infants. OBJECTIVE To determine the efficiency of the neonatal screening program for CAH in Sweden over time. DESIGN, SETTING, AND PARTICIPANTS Longitudinal prospective population-based study in Sweden. We assessed neonatal screening for CAH from January 1, 1986, through December 31, 2011, when 2 737 932 infants (99.8%) underwent testing. The CYP21A2 genotype was investigated in 219 cases with true-positive findings (94.8%). We investigated the screening outcomes for 231 patients who had true-positive findings, 43 with late diagnosis, and 1497 infants with false-positive findings. MAIN OUTCOMES AND MEASURES Sensitivity of the screening for salt-wasting CAH. The most important secondary outcome measures were the positive predictive values and recall rates for full-term and preterm infants and sensitivity for milder forms of CAH. RESULTS A total of 143 patients with salt-wasting CAH were identified; none were missed. The sensitivity was lower for milder forms of the disorder (P = .04), including 79.7% for simple virilizing forms and 32.4% for nonclassic forms. The positive predictive value was higher in full-term (25.1%) than preterm (1.4%) infants and correlated with gestational age (r = 0.98; P < .001). The recall rate in full-term infants (0.03%) was lower than that in preterm infants (0.57%) (P < .001). An analysis of previously reported results from other screening programs revealed that the sensitivity of the screening was negatively correlated with the duration of follow-up (P = .03). CONCLUSIONS AND RELEVANCE Screening for CAH was highly effective in detecting the salt-wasting form and thereby reducing mortality. Additional late-onset cases of CAH were detected in childhood and adolescence, reducing the sensitivity for milder forms. The positive predictive value was high despite a low recall rate in full-term infants. Further improvements are necessary to increase the effectiveness of screening among preterm infants.

[1]  H. Falhammar,et al.  One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. , 2013, The lancet. Diabetes & endocrinology.

[2]  W. Thomas,et al.  Comparison of One-Tier and Two-Tier Newborn Screening Metrics for Congenital Adrenal Hyperplasia , 2012, Pediatrics.

[3]  José Nélio Januário,et al.  Triagem neonatal para hiperplasia adrenal congênita , 2012 .

[4]  I. Silva,et al.  Neonatal screening for congenital adrenal hyperplasia. , 2012, Revista da Associacao Medica Brasileira.

[5]  W. Thomas,et al.  Cases of congenital adrenal hyperplasia missed by newborn screening in Minnesota. , 2012, JAMA.

[6]  S. Oberfield,et al.  Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): An update , 2012, Steroids.

[7]  J. Coste,et al.  Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003. , 2012, Archives of pediatrics & adolescent medicine.

[8]  D. Matern,et al.  Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance , 2012, European Journal of Pediatrics.

[9]  Junya Jirapradittha,et al.  Newborn screening for congenital adrenal hyperplasia in Srinagarind Hospital, Khon Kaen University, Thailand , 2011 .

[10]  H. Sallam,et al.  Congenital adrenal hyperplasia in Alexandria, Egypt: a high prevalence justifying the need for a community-based newborn screening program. , 2011, Journal of tropical pediatrics.

[11]  A. Wedell Molecular genetics of 21-hydroxylase deficiency. , 2011, Endocrine development.

[12]  R. Prasad,et al.  Preliminary Report on Neonatal Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia and Glucose-6-Phosphate Dehydrogenase Deficiency: A Chandigarh Experience , 2010, Indian journal of pediatrics.

[13]  P. White Neonatal screening for congenital adrenal hyperplasia , 2009, Nature Reviews Endocrinology.

[14]  J. Gross,et al.  The Actual Incidence of Congenital Adrenal Hyperplasia in Brazil May Not be as High as Inferred - An Estimate Based on a Public Neonatal Screening Program in the State of Goiás , 2008, Journal of pediatric endocrinology & metabolism : JPEM.

[15]  A. Chiesa,et al.  Neonatal Screening for Congenital Adrenal Hyperplasia: Experience and Results in Argentina , 2008, Journal of pediatric endocrinology & metabolism : JPEM.

[16]  D. Allen,et al.  Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls. , 2005, The Journal of pediatrics.

[17]  J. Popović,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2005, Journal for specialists in pediatric nursing : JSPN.

[18]  L. Tatò,et al.  Neonatal Screening for Congenital Adrenal Hyperplasia in North-Eastern Italy: A Report Three Years into the Program , 2005, Hormone Research in Paediatrics.

[19]  Y. Chien,et al.  Neonatal screening for congenital adrenal hyperplasia in Taiwan: a pilot study. , 2002, Journal of the Formosan Medical Association = Taiwan yi zhi.

[20]  E. Schoenle,et al.  High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. , 2002, The Journal of clinical endocrinology and metabolism.

[21]  A. Nordenström,et al.  Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants. , 2001, Pediatrics.

[22]  A. Braun,et al.  Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. , 2000, The Journal of clinical endocrinology and metabolism.

[23]  H. L. Fleshood Newborn screening for congenital adrenal hyperplasia. , 2000, Tennessee medicine : journal of the Tennessee Medical Association.

[24]  S. Berenbaum,et al.  Results of Screening 1.9 Million Texas Newborns for 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia , 1998, Pediatrics.

[25]  A. Nordenström,et al.  Benefits of Neonatal Screening for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) in Sweden , 1998, Pediatrics.

[26]  J. Sack,et al.  21-Hydroxylase deficiency: screening and incidence in Israel. , 1997 .

[27]  E. Cacciari,et al.  Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. , 1996, Pediatrics.

[28]  H. Dean,et al.  CONGENITAL ADRENAL HYPERPLASIA (CAH) NEWBORN SCREENING IN MANITOBA 1989-1994. 564 , 1996, Pediatric Research.

[29]  H. Luthman,et al.  Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. , 1994 .

[30]  A. Drash,et al.  Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. , 1977, The Journal of clinical endocrinology and metabolism.